GCG and non-alcoholic fatty liver: Different GLP-1 analogues with subcutaneous administration have been developed, namely liraglutide, semaglutide, exenatide, dulaglutide, and cotadutide, with some of them currently in a phase 2 clinical trials for NAFL or NASH.